Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study
Patients with mCRPC receiving AA were more likely to experience new-onset or worsening T2DM than those on ENZA, despite having a shorter treatment duration. Further research is required to substantiate these findings in earlier disease settings with longer treatment duration.
Authors
- Danielle Crawley (ORCID: https://orcid.org/0000-0001-7294-5634)
- Axel S. Merseburger (ORCID: https://orcid.org/0000-0001-6467-3931)
- Andrew Chilelli (ORCID: https://orcid.org/0009-0006-7086-4703)
- Nigel Rozario (ORCID: https://orcid.org/0000-0003-1510-1675)
- Amit K. Bahl (ORCID: https://orcid.org/0000-0002-8525-0310)
- A. Pranzo
- Karla Martins (ORCID: https://orcid.org/0000-0002-5306-7124)
- H. Sodatonou
- Robert Snjider
Institutions
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- Astellas Pharma (United Kingdom) (GB)
- University Hospital Schleswig-Holstein (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- World Journal of Urology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1007/s00345-024-05280-y
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09